Your browser doesn't support javascript.
loading
Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review.
Lohsiriwat, Varut; Sheikh, Parvez; Bandolon, Robert; Ren, Dong-Lin; Roslani, April Camilla; Schaible, Kassandra; Freitag, Andreas; Martin, Monique; Yaltirik, Pelin; Godeberge, Philippe.
Afiliación
  • Lohsiriwat V; Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. bolloon@hotmail.com.
  • Sheikh P; Department of Colorectal Surgery, Saifee Hospital, Mumbai, India.
  • Bandolon R; Southern Philippines Medical Center, Davao, Philippines.
  • Ren DL; Department of Colorectal Surgery, The Sixth Affiliated Hospital (Gastrointestinal and Anal Hospital), Sun Yat-Sen University, Guangzhou, China.
  • Roslani AC; Department of Surgery, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
  • Schaible K; Evidera, Waltham, MA, USA.
  • Freitag A; Evidera, London, UK.
  • Martin M; Evidera, London, UK.
  • Yaltirik P; Internal Medicine and Neuropsychiatry, Global Medical and Patient Affairs (GMPA), Servier, Suresnes, France.
  • Godeberge P; Unité d'endoscopie et de proctologie, Clinique du Trocadéro, Paris, France.
Adv Ther ; 40(1): 117-132, 2023 01.
Article en En | MEDLINE | ID: mdl-36331754
Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world evidence (RWE) studies reporting the epidemiology or recurrence of HD as well as published SLRs that combined the results of multiple studies (meta-analyses) on treatment for adults with HD. Forty of 2037 articles identified by the search were considered relevant, and four others identified by clinicians were also included (total = 44; 39 RWE, 5 meta-analyses). Review of the RWE articles revealed that HD epidemiology was determined differently between studies. Only 23 reported recurrence rates (up to 56.5%) after surgery or treatment with phlebotonic drugs (drugs that improve blood flow in veins). Most (19/23) reported recurrence rates of 20% or less. Risk factors for recurrence were similar to usual HD risk factors (e.g., constipation, male gender, age) in addition to time since treatment. Phlebotonic agents, including those made from plant extracts (micronized purified flavonoid fractions, MPFFs) improved hemorrhoidal symptoms compared with placebo or no treatment. In one meta-analysis, MPFF was the only phlebotonic to significantly reduce recurrence risk versus no treatment or placebo. Overall, more research is needed to compare treatments and determine optimal treatment duration to prevent recurrence. Author-narrated video abstract.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hemorroides Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Adult / Humans / Male Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: Tailandia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hemorroides Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Adult / Humans / Male Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: Tailandia Pais de publicación: Estados Unidos